Zimbabwe has turned down a substantial US healthcare agreement valued at $367m (£272m) over five years because of Washington's demand for sensitive data.
The decision was revealed after a official document dated December was disclosed, revealing that Head of State Emmerson Mnangagwa believed the agreement was "unbalanced".
An official representative has since explained that the US was requesting genetic material for scientific study and commercial purposes but refused to guarantee the benefits from any future vaccines.
"We must now begin the difficult and regrettable process of ending our support in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy indicated the US had donated over $1.9bn for health programmes to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has called for continued negotiations to reach a deal agreeable to all parties so the country's critical HIV treatment initiative can be sustained.
Broader Implications
This development comes after a similar situation in Kenya, where a court halted a similar health funding agreement after legal challenges were filed about the safety of Kenyans' health data.
Since returning to the presidency last year, US President Donald Trump has reduced overseas assistance and shut down the US Agency for International Development (USAID).
USAID had overseen aid for the US government, but Trump claimed its spending was "wasteful" and his government was seeking direct bilateral agreements to boost openness and accountability.
Based on reports, 16 nations in Africa have so far signed similar health pacts, representing more than $18.3bn in new funding.
Specifics of the Rejected Agreement
The funds for Zimbabwe was intended to funded "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this collaboration might have yielded extraordinary advantages for the people of Zimbabwe, particularly the 1.2 million men, women and children currently receiving antiretroviral therapy via US-supported programmes," the Ambassador added.
However, official spokesman Nick Mangwana said the arrangement was "unequal".
"Our nation was requested to surrender its genetic material and health information over an extended period, without any equivalent guarantee of benefiting from any scientific breakthroughs – such as new medicines or tests – that might be developed from that shared data," he stated.
"Effectively, our nation would supply the raw materials for scientific discovery without any assurance that the end products would be available to our population if a new health crisis emerge."
National Interest and International Frameworks
He also pointed out that the American exit from the World Health Organization (WHO) and its push of one-on-one deals were upending structures already set up through the global health agency.
The spokesperson gave as an example its Pandemic Benefit-Sharing system created to deal with potential pandemics.
"This system is intended to ensure that when a country contributes its data, the benefits – such as vaccines and treatments – are shared equitably, not monopolised solely by those with the capability to develop them."
Zimbabwe's reservations over the US deal "should not be misconstrued as anti-American sentiment," Mangwana stressed.
"We welcome further dialogue with our US partners on how future co-operation could be designed in a way that honours the sovereignty and dignity of both nations."
Health Experts Reaction
A leading public health body stated it recognised the official position, but recommended that talks should continue given that much of the country's HIV programmes depended on external financing.
"Where technical issues exist, including those relating to data governance or implementation frameworks, these can frequently be addressed through technical clarification and negotiated safeguards," the group said.
This impasse highlights the ongoing tensions between receiving vital international aid and protecting a country's data in an ever more data-driven world.